Skip to main content

Aerie Pharmaceuticals Inc

AERIDelisted Nov 21, 2022
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001337553

Aerie Pharmaceuticals Inc was delisted on Nov 21, 2022; its insiders filed their last Form 4 on Nov 21, 2022; 156 institutions reported holding it in 13F filings for Q3 2022, worth $710.6M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Aerie Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Aerie Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Aerie Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Gryska David WDirector0IndirectNov 21, 20220
McGraw Benjamin F IIIDirector0Nov 21, 20220
McHugh JulieDirector0Nov 21, 20220
McDonnell Peter JDirector0Nov 21, 20220
Kopczynski Casey C.Chief Scientific Officer0Nov 21, 20220
du Toit MichaelDirector0Nov 21, 20220
Croarkin RichardDirector0Nov 21, 20220
LaRocca JohnGeneral Counsel0Nov 21, 20220
Kannan RajChief Executive Officer0Nov 21, 20220
Calabrese JeffreyVice President of Finance0Nov 21, 20220
Lang Peter FrederickChief Financial Officer0Nov 21, 20220
Mitro Thomas APresident and COO81,418Feb 9, 20220
Hollander DavidChief R&D Officer30,749Feb 8, 20220
McGinley KathleenCHRO & VP, Corp Services23,993Feb 1, 20220
Staten ChristopherInterim CFO21,710Aug 17, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

No insider trades match these filters.